Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL5753164 | 0.86 | OPRM1 (0.89) | OPRM1KCNH2OPRK1OPRD1ALDH1A1 | |
| SCHEMBL5757445 | 0.86 | OPRM1 (0.59) | OPRM1KCNH2OPRK1OPRD1PTPN2 | |
| SCHEMBL5755630 | 0.86 | OPRM1 (0.59) | OPRM1KCNH2OPRK1OPRD1PTPN2 | |
| Acetic Acid SCHEMBL5756411 | 0.85 | OPRM1 (0.92) | OPRM1KCNH2OPRK1OPRD1ALDH1A1 | |
| SCHEMBL5753484 | 0.85 | OPRM1 (1.00) | OPRM1KCNH2OPRK1OPRD1NR3C1 | |
| Hydrochloric Acid SCHEMBL5756166 | 0.84 | OPRM1 (0.98) | OPRM1KCNH2OPRK1OPRD1NR3C1 | |
| SCHEMBL5754539 | 0.84 | OPRM1 (0.94) | OPRM1KCNH2OPRK1OPRD1NR3C1 | |
| SCHEMBL5758139 | 0.83 | OPRM1 (0.55) | OPRM1KCNH2OPRK1OPRD1GRIN1 | |
| SCHEMBL5756455 | 0.83 | OPRM1 (0.88) | OPRM1KCNH2OPRK1OPRD1NR3C1 | |
| SCHEMBL5753549 | 0.82 | OPRM1 (0.55) | OPRM1KCNH2OPRK1OPRD1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | claimed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | claimed |
| EP-1070049-B1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-06-30 | — | — | EP | claimed |
| EP-1194428-B1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | DIMENSIONAL PHARM INC (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-0161222-B1 | HETEROCYCLIC MERCAPTOCARBOXYLIC-ACID AMIDES, IMIDES AND NITRILES AS CORROSION INHIBITING AGENTS | CIBA-GEIGY AG (CH) | 1990-10-10 | — | — | EP | disclosed |
| EP-0128862-B1 | ANTI-CORROSIVE COATING COMPOSITION | CIBA-GEIGY AG (CH) | 1989-03-01 | — | — | EP | disclosed |
| EP-0183647-B1 | ANTI-CORROSIVE AQUEOUS PAINTS | CIBA-GEIGY AG (CH) | 1989-02-15 | — | — | EP | disclosed |
| EP-0183647-A1 | Anti-corrosive aqueous paints | CIBA-GEIGY AG (CH) | 1986-06-04 | — | — | EP | disclosed |
| EP-0161222-A2 | Heterocyclic mercaptocarboxylic-acid amides, imides and nitriles as corrosion inhibiting agents | CIBA-GEIGY AG (CH) | 1985-11-13 | — | — | EP | disclosed |
| EP-0128862-A2 | Anti-corrosive coating composition | CIBA-GEIGY AG (CH) | 1984-12-19 | — | — | EP | disclosed |
| EP-0001093-B1 | ORGANOTIN COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INTERMEDIATE PRODUCTS FOR STABILISERS | CIBA-GEIGY AG (CH) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885KCNH2 3004/4885OPRK1 2/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885KCNH2 3004/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.